Live-attenuated varicella vaccine (Q34218642)

31 July 2017

1 reference

title

Live-attenuated varicella vaccine (English)

1 reference

31 July 2017

1 reference

Gershon AA

1

1 reference

31 July 2017

1 March 2001

1 reference

Infectious Disease Clinics of North America

31 July 2017

1 reference

31 July 2017

15

1 reference

31 July 2017

65-81, viii

1 reference

31 July 2017

1

1 reference

Live attenuated varicella vaccine

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Edmonston-Zagreb measles vaccine: A good vaccine with an image problem

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Varicella and zoster in children after kidney transplantation: long-term results of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Administration of live varicella vaccine to children wtih leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Varicella vaccination of health-care workers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Detection of antibodies to varicella-zoster virus using a latex agglutination assay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Live attenuated varicella vaccine. Efficacy for children with leukemia in remission

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Immunization of healthy adults with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Live Attenuated Varicella Vaccine: Protection in Healthy Adults Compared with Leukemic Children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Herpes zoster with postherpetic neuralgia--persisting pain and frustration

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Herpes zoster in an adult recipient of live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Use of live varicella vaccine in children with acute leukaemia or other malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Biologic and Biophysical Markers of a Live Varicella Vaccine Strain (Oka): Identification of Clinical Isolates from Vaccine Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Analysis of varicella-zoster virus DNAs of clinical isolates by endonuclease HpaI.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Transmission of varicella-zoster virus from a vaccinee with leukemia, demonstrated by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

A long-term prospective study of varicella vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

The risk of zoster after varicella vaccination in children with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Immune response of elderly individuals to a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Herpes zoster after varicella immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Reactivated and latent varicella-zoster virus in human dorsal root ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Antibody assays suitable for assessing immune responses to live varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Modification of chicken pox in family contacts by administration of gamma globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Postexposure varicella vaccination in siblings of children with active varicella

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Live vaccine used to prevent the spread of varicella in children in hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Efficacy of high-titer live attenuated varicella vaccine in healthy young children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Varicella: historical perspective and clinical overview

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Clinical trials of varicella vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Varicella-zoster virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Herpes zoster following varicella vaccine in a child with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

Seroconversion rates in healthcare workers using a latex agglutination assay after varicella virus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970268-3

7 January 2021

10.1016/S0891-5520(05)70268-3

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11301823